Kymansis
Epalinges
About Kymansis
Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 18 million lives each year. CVDs are a group of disorders impacting the heart and blood vessels. Identifying those at highest risk of CVDs quickly is paramount in preventing premature death. For the most part, diagnosis of CVDs still relies on lengthy or invasive procedures, bulky equipment, and specialised expertise. As a result, millions of people go undiagnosed each year. Blood pressure is the most widely-used non-invasive marker – but on its own, it cannot provide a full picture of cardiovascular health.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $124.8K
- Last round: Grant (Aug 2025)
Canonical: https://fsome.com/organization/kymansis-192239 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.